CBRE Groupの空売り状況は、投資家がCBRE Groupの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

CBRE Group (NYSE:CBRE) 株価情報, 空売り情報

CBRE Group

CBRE Group provides a wide range of real estate services to owners, occupants, and investors worldwide, including leasing, property and project management, and capital markets advisory. CBRE's investment management arm manages over $140 billion for clients across diverse public and private real estate strategies.

CBRE Group Inc

CBRE Global Real Estate Income Fund Common Shares of Beneficial Interest

CBRE Clarion Global Real Estate Income Fund

RBC Capital analyst Conor McNamara maintains Repligen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGEN#NASDAQ">RGEN</a>) with a Outperform and raises the price target from $203 to $205.

News

Price Target

Analyst Ratings

RGEN

RBC Capital Maintains Outperform on Repligen, Raises Price Target to $205

AAPL

Apple Intelligence Comes To Apple Vision Pro In April

<a href="https://www.apple.com/newsroom/2025/02/apple-intelligence-expands-to-more-languages-and-regions-in-april/#:~:text=Apple%20Intelligence%2C%20the%20personal%20intelligence,English%20for%20Singapore%20and%20India.">https://www.apple.com/newsroom/2025/02/apple-intelligence-expands-to-more-languages-and-regions-in-april/#:~:text=Apple%20Intelligence%2C%20the%20personal%20intelligence,English%20for%20Singapore%20and%20India.</a>
&nbsp;
Apple Intelligence, the personal intelligence system that delivers helpful and relevant intelligence, will soon be available in more languages, including French, German, Italian, Portuguese (Brazil), Spanish, Japanese, Korean, and Chinese (simplified) — as well as localized English for Singapore and India.
These new languages will be accessible in nearly all regions around the world with the release of iOS 18.4, iPadOS 18.4, and macOS Sequoia 15.4 in April, and developers can start to test these releases today.
With the upcoming software updates, iPhone and iPad users in the EU will have access to Apple Intelligence features for the first time, and Apple Intelligence will expand to a new platform in U.S. English with <a href="https://www.apple.com/newsroom/2025/02/apple-intelligence-comes-to-apple-vision-pro-in-april/">Apple Vision Pro</a>&nbsp;—&nbsp;helping users communicate, collaborate, and express themselves in entirely new ways.
Apple Intelligence marks an extraordinary step forward for privacy in AI and is designed to protect users' privacy at every step. It starts with on-device processing, meaning that many of the models that power Apple Intelligence run entirely on the device. For requests that require access to larger models, Private Cloud Compute extends the privacy and security of iPhone into the cloud to unlock even more intelligence.
Apple Intelligence will continue to expand with new features in the coming months, including more capabilities for Siri.

Global

'Apple Intelligence On iPhone, iPad, And Mac Expands To More Languages And Regions In April'

UBS analyst Kunal Madhukar maintains Global E Online (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLBE#NASDAQ">GLBE</a>) with a Buy and lowers the price target from $68 to $64.

GLBE

UBS Maintains Buy on Global E Online, Lowers Price Target to $64

RBC Capital analyst Brian Abrahams maintains Prothena Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) with a Sector Perform and lowers the price target from $24 to $20.

PRTA

RBC Capital Maintains Sector Perform on Prothena Corp, Lowers Price Target to $20

WIIM

CENX

Century Aluminum shares are trading lower. The company reported Q4 financial results.

The U.S. Food and Drug Administration (FDA) approved Mirum Pharmaceuticals, Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIRM#NASDAQ">MIRM</a>) drug to treat CTX, a very rare lipid storage disease.
CTX is a genetic metabolic disorder caused by a mutation in a gene called CYP27A1, resulting in a deficiency of the enzyme that is important to the body's ability to break down fats.
Ctexli (chenodiol) is the first FDA-<a href="https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-cerebrotendinous-xanthomatosis-rare-lipid-storage-disease#:~:text=Today%2C%20the%20U.S.%20Food%20and,very%20rare%20lipid%20storage%20disease." target="_blank" rel="noreferrer noopener">approved</a> drug to treat cerebrotendinous xanthomatosis (CTX) in adults.
Also Read: <a target="_blank" href="https://www.benzinga.com/media/25/02/43887175/disney-appoints-former-paramount-exec-daria-cercek-to-lead-live-action-films-reshaping-studio-leadership" rel="noreferrer noopener">Disney Appoints Former Paramount Exec Daria Cercek to Lead Live-Action Films, Reshaping Studio Leadership</a>
Due to reduced bile acid production in the liver, patients with CTX are unable to break down cholesterol in a normal way, resulting in deposition of atypical cholesterol metabolites in various places in the body including the brain, liver, skin and tendons, leading to damage to those organs and tissues.
Ctexli works to replace deficient levels of one of the bile acids, reducing the abnormal deposits of cholesterol metabolites thought to be responsible for clinical abnormalities in CTX.
The efficacy of Ctexli was evaluated in a double-blind, placebo-controlled, randomized crossover withdrawal trial.
The 24-week trial demonstrated that treatment with Ctexli, 250 milligrams three times per day, significantly reduced plasma cholestanol and urine 23S-pentol (cholesterol metabolites markedly increased in CTX patients) compared to placebo treatment.
The prescribing information for Ctexli includes a warning for liver toxicity in all patients with increased risk for liver damage in patients with pre-existing liver disease or bile duct abnormalities.
Patients should obtain liver blood tests before starting treatment, annually while on treatment, and as clinically indicated.
In January, Mirum Pharmaceuticals reported preliminary net product sales of approximately $99 million in the fourth quarter, including approximately $64 million in Livmarli net sales and approximately $35 million <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/b42943888/mirum-pharmaceuticals-announces-preliminary-unaudited-2024-net-product-sales-and-cash-balance-and-" rel="noreferrer noopener">from Cholbam and Chenodal</a>.
The company expects 2025 global net product sales of approximately $420 million to $435 million and positive cash flow from operations.
Price Action: Mirium stock is up 0.10% at $53.22 at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/health-care/25/02/43883818/glaukos-delivers-mixed-q4-results-analyst-sees-growing-investor-interest-during-transition" target="_blank" rel="noreferrer noopener">Glaukos Delivers Mixed Q4 Results, Analyst Sees Growing Investor Interest During Transition</a></li>
</ul>
Image: Shutterstock

Biotech

Health Care

General

MIRM

FDA Approves Mirum Pharmaceuticals' Drug As First For Genetic Disorder With Inability To Break-Down Cholesterol

Westlake Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WLK#NYSE">WLK</a>) will release its fourth-quarter financial results, before the opening <a href="https://www.benzinga.com/quote/WLK/earnings">bell, on Monday, Feb. 24, 2025.</a>
Analysts expect the Houston, Texas-based company to report quarterly earnings at $1.17 per share, up from 53 cents per share in the year-ago period. Westlake projects quarterly revenue of $2.97 billion, compared to $2.83 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Nov. 5, the company posted weaker-than-expected third-quarter earnings.
Westlake shares fell 1.9% to close at $111.40 on Thursday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/WLK/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li>Citigroup analyst Patrick Cunningham upgraded the stock from Neutral to Buy and cut the price target from $152 to $140 on Dec. 18, 2024. This analyst has an accuracy rate of 63%.</li>
<li>BMO Capital analyst John McNulty maintained a Market Perform rating and lowered the price target from $171 to $165 on Nov. 13, 2024. This analyst has an accuracy rate of 63%.</li>
<li>UBS analyst Joshua Raskin maintained a Neutral rating and cut the price target from $160 to $144 on Nov. 6, 2024. This analyst has an accuracy rate of 80%.</li>
<li>Wells Fargo analyst Michael Sison maintained an Overweight rating and cut the price target from $180 to $160 on Nov. 6, 2024. This analyst has an accuracy rate of 67%.</li>
<li>JP Morgan analyst Jeffrey Zekauskas maintained an Underweight rating and raised the price target from $123 to $135 on Aug. 15, 2024. This analyst has an accuracy rate of 67%.</li>
</ul>
Considering buying WLK stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="597" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/21040916/image-177-1024x597.png" alt="" class="wp-image-792653" style="width:640px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/21040916/image-177-1024x597.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/21040916/image-177-300x175.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/21040916/image-177-768x448.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/21040916/image-177.png 1093w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43864993/top-3-health-care-stocks-you-may-want-to-dump-in-february">Top 3 Health Care Stocks You May Want To Dump In February</a></li>
</ul>

Earnings

Markets

Trading Ideas

Top Wall Street Forecasters Revamp Westlake Price Expectations Ahead Of Q4 Earnings

UBS analyst Taylor McGinnis maintains RingCentral (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RNG#NYSE">RNG</a>) with a Neutral and lowers the price target from $40 to $38.

UBS Maintains Neutral on RingCentral, Lowers Price Target to $38

RBC Capital analyst Rishi Jaluria maintains NICE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NICE#NASDAQ">NICE</a>) with a Outperform and lowers the price target from $260 to $200.

NICE

RBC Capital Maintains Outperform on NICE, Lowers Price Target to $200

VKTX

Viking Therapeutics shares are trading higher amid unconfirmed M&A rumors.

UBS analyst Michael Lasser maintains Walmart (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) with a Buy and lowers the price target from $113 to $112.

UBS Maintains Buy on Walmart, Lowers Price Target to $112

RBC Capital analyst Darko Mihelic maintains Manulife Financial (TSX:<a class="ticker" href="https://www.benzinga.com/stock/MFC#TSX">MFC</a>) with a Outperform and raises the price target from C$49 to C$51.

TSX:MFC

RBC Capital Maintains Outperform on Manulife Financial, Raises Price Target to C$51

Macro Economic Events

Econ #s

Economics

U.S. Baker Hughes Oil Rig Count +7 To 488; U.S. Baker Hughes NatGas Rig Count -2 To 99; U.S. Baker Hughes Horizonal Drilling Rig Count +6 At 530

All three major U.S. stock indices are down Friday as traders reacted to several sets of fresh data that raised concerns about<a href="https://www.benzinga.com/25/02/43877634/us-stocks-fluctuate-in-preopen-volatility-doesnt-equal-financial-loss-unless-you-sell-says-expert"> the economic outlook.&nbsp;</a>
The University of Michigan consumer sentiment index fell to 64.7 in January, a decline of 10% and a steeper drop than expected. The 5-year inflation outlook in the survey is the highest since 1995 at 3.5% 
Existing home sales sank by 4.9% to a seasonally adjusted rate of 4.08 million in January, the sharpest decline in seven months, according to Trading Economics.&nbsp;
Read Next: <a href="https://www.benzinga.com/general/market-summary/25/02/43884153/us-services-drop-sharply-darkening-picture-of-high-prices-uncertainty-economist-says">US Services Drop Sharply: &#8216;Darkening Picture&#8217; Of High Prices, Uncertainty, Economist Says</a>
February's flash S&amp;P Global PMIs released <a href="https://www.benzinga.com/general/market-summary/25/02/43884153/us-services-drop-sharply-darkening-picture-of-high-prices-uncertainty-economist-says">Friday morning </a>revealed a sharp, unexpected drop in services and raised concerns about the health of the private sector.&nbsp;
"The upbeat mood seen among US businesses at the start of the year has evaporated, replaced with a darkening picture of heightened uncertainty, stalling business activity and rising prices," said Chris Williamson, chief business economist at S&amp;P Global Market Intelligence.&nbsp;
Natural gas futures rose another 4.5% Friday to $4.3/MMBtu, hitting a 25-month high as cold weather increased heating demand and disrupted production. The United States Natural Gas Fund LP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNG#NYSE">UNG</a>), tracking the daily price movements of natural gas futures contracts, climbed 3.2%.&nbsp;
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) was volatile as crypto markets reacted to a $1.4 billion Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) hack targeting Bybit&#8217;s cold wallet, <a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43886224/bybit-founder-confirms-1-4-billion-ethereum-hack-blames-masked-transaction">one of the largest</a> security breaches in recent history.
<h2 class="wp-block-heading">Friday's Performance In Major US Indices, ETFs</h2>
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1 day % chg.</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>19,753.44</td>
<td>-1.05%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>6,069.73</td>
<td>-0.78%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>43,739.57</td>
<td>-0.99%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,231.48</td>
<td>-1.34%</td>
</tr>
</tbody>
</table>
</figure>
<h2 class="wp-block-heading">Friday's Stock Movers:&nbsp;</h2>
Shares of UnitedHealth Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) slumped nearly 9% after the Wall Street Journal reported the Department of Justice launched an investigation into the company&#8217;s Medicare billing practices.
Stocks reacting to company earnings reports included:&nbsp;
<ul>
<li>Solaris Energy Infrastructure, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SEI#NYSE">SEI</a>) </li>
<li>Iamgold Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IAG#NYSE">IAG</a>) </li>
<li>Celsius Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELH#NASDAQ">CELH</a>) </li>
<li>Glaukos Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>) </li>
<li>MercadoLibre, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MELI#NASDAQ">MELI</a>) </li>
<li>The RealReal, Inc. (NASADQ:REAL) </li>
<li>Nu Holdings Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NU#NYSE">NU</a>)</li>
<li>Globant S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLOB#NYSE">GLOB</a>) </li>
<li>Block, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYZ#NYSE">XYZ</a>) </li>
<li>Rivian Automotive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) </li>
</ul>
Companies reporting on Monday included:&nbsp;
<ul>
<li>Domino&#8217;s Pizza Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NASDAQ">DPZ</a>) </li>
<li>Zoom Communications, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZM#NASDAQ">ZM</a>) </li>
<li>Diamondback Energy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FANG#NASDAQ">FANG</a>) </li>
<li>Kosmos Energy Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KOS#NYSE">KOS</a>) </li>
<li>Summit Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>) </li>
<li>Hovnanian Enterprises, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HOV#NYSE">HOV</a>) </li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43836832/trump-administration-orders-sweeping-pentagon-cuts-defense-sector-stocks-on-watch"> Trump Administration Orders Sweeping Pentagon Cuts: Palantir, Lockheed Martin, General Dynamics Among Stocks On Watch</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Market Summary

Sector ETFs

Broad U.S. Equity ETFs

Movers

ETFs

Real Estate

$BTC

$ETH

CELH

FANG

GKOS

GLOB

MELI

REAL

RIVN

SMMT

Consumer Sentiment Drops 10%, UnitedHealth Under Investigation: What's Driving Markets Friday?

Citigroup analyst Jon Tower maintains Texas Roadhouse (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXRH#NASDAQ">TXRH</a>) with a Buy and raises the price target from $212 to $213.

TXRH

Citigroup Maintains Buy on Texas Roadhouse, Raises Price Target to $213

RBC Capital analyst Darko Mihelic maintains Manulife Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MFC#NYSE">MFC</a>) with a Outperform and raises the price target from $49 to $51.

RBC Capital Maintains Outperform on Manulife Financial, Raises Price Target to $51

5 analysts have shared their evaluations of DigitalBridge Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DBRG#NYSE">DBRG</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $17.0, a high estimate of $20.00, and a low estimate of $15.00. A decline of 11.69% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1740160857_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The standing of DigitalBridge Gr among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Greg Miller</td>
<td>Citizens Capital Markets</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$16.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Greg Miller</td>
<td>JMP Securities</td>
<td>Announces</td>
<td>Market Outperform</td>
<td>$16.00</td>
<td>-</td>
</tr>
<tr>
<td>Richard Choe</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$18.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Daniel Day</td>
<td>B. Riley Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$20.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Anthony Hau</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$15.00</td>
<td>$17.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to DigitalBridge Gr. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of DigitalBridge Gr compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of DigitalBridge Gr's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into DigitalBridge Gr's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/DBRG/analyst-ratings?utm_source=benzinga-insights&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on DigitalBridge Gr analyst ratings.</a>
<h2>Unveiling the Story Behind DigitalBridge Gr</h2>
DigitalBridge Group Inc is a developer of alternative asset manager dedicated to investing in digital infrastructure. The company's platform invests in and operates businesses across the digital ecosystem, including cell towers, data centers, fiber, small cells, and edge infrastructure, to provide clients with funds for digital infrastructure real estate infrastructure.
<h3>DigitalBridge Gr: Delving into Financials</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Negative Revenue Trend: Examining DigitalBridge Gr's financials over 3 months reveals challenges. As of 30 September, 2024, the company experienced a decline of approximately -71.02% in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Financials sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -1.16%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -0.07%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): DigitalBridge Gr's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -0.03%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.29, DigitalBridge Gr adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Significance of Analyst Ratings Explained</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

DBRG

Demystifying DigitalBridge Gr: Insights From 5 Analyst Reviews

Providing a diverse range of perspectives from bullish to bearish, 7 analysts have published ratings on Valaris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VAL#NYSE">VAL</a>) in the last three months.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $49.71, along with a high estimate of $59.00 and a low estimate of $40.00. A 19.82% drop is evident in the current average compared to the previous average price target of $62.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1740160850_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The standing of Valaris among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Charles Minervino</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$47.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Scott Gruber</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$48.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>James West</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$59.00</td>
<td>$87.00</td>
</tr>
<tr>
<td>Eddie Kim</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$49.00</td>
<td>$59.00</td>
</tr>
<tr>
<td>Nikhil Gupta</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$47.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>Arun Jayaram</td>
<td>JP Morgan</td>
<td>Announces</td>
<td>Underweight</td>
<td>$40.00</td>
<td>-</td>
</tr>
<tr>
<td>Nikhil Gupta</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$58.00</td>
<td>$71.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Valaris. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Valaris compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Valaris's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
For valuable insights into Valaris's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/VAL/analyst-ratings?utm_source=benzinga-insights&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Valaris analyst ratings.</a>
<h2>Unveiling the Story Behind Valaris</h2>
Valaris Ltd is the industry leader in offshore drilling services across all water depths and geographies. It is a high-quality rig fleet of ultra-deepwater drillships, versatile semisubmersibles and modern shallow-water jackups. It operates in Floaters, Jackups, ARO and Others. Its majority of the revenue comes from Floaters segment which includes drillships and semisubmersible rigs.
<h3>Key Indicators: Valaris's Financial Health</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Revenue Challenges: Valaris's revenue growth over 3 months faced difficulties. As of 31 December, 2024, the company experienced a decline of approximately -9.13%. This indicates a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Energy sector.
Net Margin: Valaris's net margin is impressive, surpassing industry averages. With a net margin of 22.88%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Valaris's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 6.13% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Valaris's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 3.05%, the company showcases efficient use of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 0.48, Valaris adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Beyond The Numbers: 7 Analysts Discuss Valaris Stock

Analysts' ratings for LKQ (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LKQ#NASDAQ">LKQ</a>) over the last quarter vary from bullish to bearish, as provided by 4 analysts.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated LKQ and provided 12-month price targets. The average target is $54.25, accompanied by a high estimate of $60.00 and a low estimate of $48.00. Observing a downward trend, the current average is 0.46% lower than the prior average price target of $54.50. 
<img src="https://www.benzinga.com/files/images/story/2025/1740160841_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A clear picture of LKQ's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Samik Chatterjee</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$49.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Gary Prestopino</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$60.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Gary Prestopino</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$60.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Samik Chatterjee</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$48.00</td>
<td>$50.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to LKQ. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of LKQ compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of LKQ's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/LKQ/analyst-ratings?utm_source=benzinga-insights&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on LKQ analyst ratings.</a>
<h2>All You Need to Know About LKQ</h2>
Since forming in 1998 to consolidate the auto salvage business in the United States, LKQ has developed into a leading distributor of aftermarket and recycled auto parts with around 1,700 facilities across North America and Europe. The company primarily sells into the professional channel and offers an assortment of collision and mechanical parts to both body shops and mechanical repair shops. It also continues to operate more than 70 LKQ pick-your-part junkyards. Separate from the self-service business, LKQ typically purchases around 250,000 salvage vehicles annually that are used to extract vehicle parts for resale.
<h3>Financial Milestones: LKQ's Journey</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Revenue Growth: LKQ's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 0.45%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Consumer Discretionary sector.
Net Margin: LKQ's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 5.33%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 3.09%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): LKQ's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.25% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: With a high debt-to-equity ratio of 0.93, LKQ faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>The Basics of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Deep Dive Into LKQ Stock: Analyst Perspectives (4 Ratings)

Press Releases

NYLI CBRE Global Infrastructure Megatrends Term Fund (NYSE: MEGI) Declares Monthly Distribution for December 2024 and Availability of 19(a) Notice

CBRE Group Completes Turner & Townsend/Project Management Combination; Vincent Clancy Joins CBRE Board of Directors

CBRE Group, Inc. Announces Details of Conference Call and Webcast for Fourth Quarter and Full-Year 2024 Financial Results

CBRE Global Real Estate Income Fund (NYSE: IGR) Declares Monthly Distributions for January, February and March and Announces a Webinar with Portfolio Management

CBRE Group to Acquire Industrious, Create New Business Segment

NYLI CBRE Global Infrastructure Megatrends Term Fund (NYSE: MEGI) Declares Monthly Distribution for January 2025 and Availability of 19(a) Notice

Gateway Fiber and WANRack Unite to Connect More Communities in Strategic Merger

CBRE Group, Inc. Reports Financial Results for Q4 and Full Year 2024

NYLI CBRE Global Infrastructure Megatrends Term Fund (NYSE: MEGI) Declares Monthly Distribution for February 2025 and Availability of 19(a) Notice

CBRE Group, Inc. to Present at Morgan Stanley 2025 Commercial Real Estate Conference

CBRE

MEGI

Altisource Portfolio Solutions S.A. - Common Stock

Altisource Portfolio

KE Holdings Inc American Depositary Shares (each representing three Class A Ordinary Shares)

Comments

CBRE Group

空売り

CBRE Group (NYSE:CBRE) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル